Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOS NASDAQ:IRTC NASDAQ:LMAT NYSE:STVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$94.39+0.5%$95.38$77.10▼$163.71$5.50B0.77755,538 shs678,612 shsIRTCiRhythm Technologies$176.58+3.2%$151.49$55.92▼$177.00$5.46B1.1416,171 shs557,858 shsLMATLeMaitre Vascular$94.56-0.5%$88.05$71.42▼$109.58$2.16B0.79214,240 shs139,206 shsSTVNStevanato Group€23.38+3.2%€24.13€17.12▼€28.00€7.08B0.55341,292 shs1.06 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos+0.38%-1.04%+7.85%+2.02%-29.03%IRTCiRhythm Technologies+3.21%+4.00%+7.03%+21.59%+159.68%LMATLeMaitre Vascular-0.49%-1.17%+12.09%+13.38%+8.09%STVNStevanato Group+3.36%+4.66%-8.60%+0.82%+6.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.782 of 5 stars4.44.00.04.43.61.70.6IRTCiRhythm Technologies1.5835 of 5 stars2.51.00.00.04.10.80.6LMATLeMaitre Vascular3.03 of 5 stars1.23.03.30.02.32.52.5STVNStevanato GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.79Moderate Buy$127.4235.00% UpsideIRTCiRhythm Technologies 3.00Buy$163.82-7.23% DownsideLMATLeMaitre Vascular 2.40Hold$97.603.21% UpsideSTVNStevanato Group 2.83Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest LMAT, STVN, GKOS, and IRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$180.00 ➝ $193.008/21/2025IRTCiRhythm TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$167.00 ➝ $183.008/20/2025IRTCiRhythm TechnologiesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$200.008/15/2025GKOSGlaukosZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/6/2025LMATLeMaitre VascularCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$92.00 ➝ $95.008/6/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$95.008/1/2025IRTCiRhythm TechnologiesWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/1/2025IRTCiRhythm TechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$145.00 ➝ $190.008/1/2025IRTCiRhythm TechnologiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$139.00 ➝ $170.008/1/2025IRTCiRhythm TechnologiesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$130.00 ➝ $180.008/1/2025IRTCiRhythm TechnologiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$151.00 ➝ $180.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M14.12N/AN/A$13.34 per share7.08IRTCiRhythm Technologies$591.84M9.59N/AN/A$3.23 per share54.67LMATLeMaitre Vascular$219.86M9.74$2.37 per share39.92$16.02 per share5.90STVNStevanato Group€1.19B5.93€0.77 per share30.48€5.24 per share4.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%11/3/2025 (Estimated)IRTCiRhythm Technologies-$113.29M-$2.93N/AN/AN/A-14.06%-90.03%-8.52%10/29/2025 (Estimated)LMATLeMaitre Vascular$44.04M$2.0645.9043.582.4520.08%13.67%9.14%10/30/2025 (Estimated)STVNStevanato Group€127.45M€0.5443.3040.312.1711.73%10.34%6.21%N/ALatest LMAT, STVN, GKOS, and IRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025LMATLeMaitre Vascular$0.57$0.60+$0.03$0.60$62.48 million$63.15 million7/31/2025Q2 2025IRTCiRhythm Technologies-$0.53-$0.32+$0.21-$0.44$173.94 million$186.69 million7/30/2025Q2 2025GKOSGlaukos-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/AIRTCiRhythm TechnologiesN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.85%N/A38.83%14 YearsSTVNStevanato GroupN/AN/AN/AN/A1 YearsLatest LMAT, STVN, GKOS, and IRTC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/30/2025LMATLeMaitre Vascularquarterly$0.200.9%8/21/20258/21/20259/4/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.095.514.69IRTCiRhythm Technologies6.255.024.88LMATLeMaitre Vascular0.4613.9611.74STVNStevanato Group0.251.791.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%IRTCiRhythm TechnologiesN/ALMATLeMaitre Vascular84.64%STVNStevanato GroupN/AInsider OwnershipCompanyInsider OwnershipGKOSGlaukos6.40%IRTCiRhythm Technologies0.68%LMATLeMaitre Vascular9.50%STVNStevanato GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.35 million53.68 millionOptionableIRTCiRhythm Technologies2,00032.13 million31.91 millionOptionableLMATLeMaitre Vascular49022.64 million20.49 millionOptionableSTVNStevanato Group5,521302.84 millionN/AOptionableLMAT, STVN, GKOS, and IRTC HeadlinesRecent News About These CompaniesStevanato Group to Participate in Upcoming Investor ConferencesSeptember 2 at 5:59 PM | businesswire.comStevanato Group S.p.A. $STVN Shares Purchased by Raymond James Financial Inc.September 2 at 3:50 AM | marketbeat.comTri Locum Partners LP Decreases Stake in Stevanato Group S.p.A. $STVNAugust 30, 2025 | marketbeat.comChamplain Investment Partners LLC Takes $15.74 Million Position in Stevanato Group S.p.A. $STVNAugust 30, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases 91,663 Shares of Stevanato Group S.p.A. $STVNAugust 29, 2025 | marketbeat.comUSNA or STVN: Which Is the Better Value Stock Right Now?August 28, 2025 | zacks.com633,887 Shares in Stevanato Group S.p.A. $STVN Purchased by MetLife Investment Management LLCAugust 28, 2025 | marketbeat.comHere’s Why Artisan Small Cap Fund Increased its Holdings in Stevanato Group S.p.A. (STVN)August 25, 2025 | insidermonkey.comT. Rowe Price Investment Management Inc. Has $76.47 Million Stock Position in Stevanato Group S.p.A. $STVNAugust 25, 2025 | marketbeat.comInvesco Ltd. Invests $19.07 Million in Stevanato Group S.p.A. $STVNAugust 24, 2025 | marketbeat.comStevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 21, 2025 | marketbeat.comStevanato Group S.p.A. $STVN Shares Acquired by LPL Financial LLCAugust 20, 2025 | marketbeat.comDeutsche Bank AG Has $19.19 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)August 15, 2025 | marketbeat.comUSNA vs. STVN: Which Stock Is the Better Value Option?August 12, 2025 | zacks.com93,709 Shares in Stevanato Group S.p.A. (NYSE:STVN) Bought by Zions Bancorporation National Association UTAugust 10, 2025 | marketbeat.comBrokers Set Expectations for Stevanato Group Q3 EarningsAugust 9, 2025 | marketbeat.comBlair William & Co. IL Purchases 137,625 Shares of Stevanato Group S.p.A. (NYSE:STVN)August 9, 2025 | marketbeat.comWilliam Blair Predicts Stronger Earnings for Stevanato GroupAugust 8, 2025 | marketbeat.comJackson Square Partners LLC Has $23.65 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)August 8, 2025 | marketbeat.comCenterBook Partners LP Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)August 8, 2025 | marketbeat.comMutual of America Capital Management LLC Grows Holdings in Stevanato Group S.p.A. (NYSE:STVN)August 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMAT, STVN, GKOS, and IRTC Company DescriptionsGlaukos NYSE:GKOS$94.38 +0.44 (+0.46%) Closing price 09/3/2025 03:59 PM EasternExtended Trading$94.46 +0.07 (+0.08%) As of 09/3/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.iRhythm Technologies NASDAQ:IRTC$176.58 +5.50 (+3.21%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$176.69 +0.11 (+0.06%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.LeMaitre Vascular NASDAQ:LMAT$94.56 -0.47 (-0.49%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$94.48 -0.08 (-0.08%) As of 09/3/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Stevanato Group NYSE:STVN€23.38 +0.73 (+3.22%) As of 09/3/2025 03:58 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
